Current treatment status-Undergoing active treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

Evaluating pembrolizumab for patients with reoccurring classical Hodgkin’s lymphoma

Posted by on Sep 2, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with classical Hodgkin’s lymphoma (cHL) that came back after initial treatment. This study concluded that pembrolizumab was effective for these patients, with manageable side effects. Some background First-line chemotherapy is highly...

Read More

Evaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma

Posted by on Aug 19, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Comparing outcomes in patients with chronic lymphocytic leukemia with detectable and undetectable minimal residual disease

Posted by on Jul 31, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes for patients with chronic lymphocytic leukemia who achieved detectable and undetectable minimal residual disease (MRD).   This study concluded that patients with undetectable MRD had better outcomes than those with detectable MRD.  Some background Minimal...

Read More

EndoPredict – can this prognostic test predict treatment success in breast cancer?

Posted by on May 30, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC.  Some background Breast cancer (BC) is one of the most common cancers. BC treatment...

Read More

Evaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma

Posted by on May 11, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated  isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...

Read More

Evaluating scoring systems used to predict outcomes for patients with advanced HL

Posted by on Apr 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...

Read More

Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?

Posted by on Jan 12, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...

Read More

Risk of hepatitis B reactivation in patients with lymphomas receiving obinutuzumab or rituximab

Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of reactivating hepatitis B (HBV) infection in patients with lymphoma treated with obinutuzumab (Gazyva) or rituximab (Rituxan). Researchers found that HBV infection was reactivated in some of these patients but treatment options are available. Some background Lymphoma is a cancer of the immune system....

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More